Posts

Posted on

Learn how to create sustainable community-owned enterprises with help from new book

John Makilya shares how low income people can pool resources in ‘Sustainable Community-Owned Enterprises’

BARNSTABLE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — John Makilya demonstrates how selected projects in water, beef, dairy, savings and credit, coffee, and other sectors qualify as sustainable community-owned enterprises in his new book titled “Sustainable Community-Owned Enterprises” (published by Archway Publishing).

 

The book lays out the ingredients of a successful and sustainable community-owned enterprise. Makilya makes a brief account of the concept of indigenous communities working together for a common good “Sustainable Community-Owned Enterprises” models successful community-owned enterprises by employing all the necessary ingredients for a profitable and beneficial enterprise. Makilya also includes an account of unsuccessful community-owned enterprises.

 

“I would like readers to learn that low income people, who do not have resources to invest in the stock market, can pool resources and employ professional management to run their enterprise and distribute benefits to their members just like a corporation distributes dividends to its stockholders,” the author says.

 

Makilya is available for purchase online at the Archway link above, at Barnes & Noble and on Amazon at: https://www.amazon.com/Sustainable-Community-owned-Enterprises-John-Makilya/dp/1480894745

 

“Sustainable Community-Owned Enterprises”

By John Makilya

Softcover | 7.5 x 9.25 in | 162 pages | ISBN 9781480894747

E-Book | 162 pages | ISBN 9781480894730

Available at Amazon and Barnes & Noble

 

About the Author

John Makilya native of Kenya, has spent the bulk of his career working with communities to establish and implement sustainable community-owned enterprises. He designed and implemented management, accounting and financial control systems for various community-owned enterprises- in financial services, dairy, water, beef cattle, fisheries, and wildlife/tourist sectors. Upon installation of the management systems, Makilya hired and trained personnel on the systems and phased out his services depending on need but retained a monitoring role in the enterprise until it was established it would run without much oversight. He had a successful career in Kenya before relocating with his family to the USA. In the USA Makilya changed his career to financial services. He is also the author of “Life Lessons of an Immigrant.”

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment 



Marketing Services
Archway Publishing
844-669-3957
[email protected]

Posted on

Mkango Receives TSX Venture Exchange Approval for Talaxis Cashless Warrant Exercise

LONDON and VANCOUVER, British Columbia, Jan. 07, 2021 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) is pleased to announce that it has received TSX-V approval for the cashless warrant exercise by Talaxis Limited (“Talaxis”) announced on 4 January 2021, whereby Talaxis will be issued with 1,000,000 Shares (“New Shares”) in lieu of payment for 12,000,000 Shares at 6.6 pence. This significantly reduces the dilution to other Mkango shareholders and avoids the Company issuing 12,000,000 shares at a significant discount to the current market price of Mkango Shares.

Following the issuance of the New Shares to Talaxis pursuant to the amended warrant, Talaxis will increase its ownership of Mkango from 14,285,715 shares to 15,285,715 shares post-warrant exercise, representing an increase from 10.7% to 11.3% of the issued and outstanding shares. Talaxis maintains its 49% ownership in the Songwe Hill Rare Earths Project (the “Project”) and its option to acquire a further 26% interest in the Project by arranging financing for project development including funding the equity component thereof.            

The New Shares issued pursuant to the warrant exercise, will rank pari passu with the existing common shares. Application has been made for the New Shares issued to Talaxis to be admitted to trading on AIM (“Admission”). It is expected that Admission will become effective and dealings in the New Shares will commence on or around January 12, 2021. The New Shares will also trade on the TSX-V.

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6.1R) the Company hereby notifies the market that immediately following Admission of the New Shares, its issued share capital will consist of 135,200,721 shares. The Company does not hold any shares in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

A
bou
t
M
k
an
go

Mkango’s primary business is exploration for rare earth elements and associated minerals in the Republic of Malawi, a country whose hospitable people have earned it a reputation as “the warm heart of Africa”. The Company holds interests in four exclusive prospecting licenses in Malawi: the Phalombe licence, the Thambani licence, the Chimimbe Hill licence and the Mchinji licence.

The main exploration target in the 51% held Phalombe licence is the Songwe Hill rare earths deposit. This features carbonatite-hosted rare earth mineralisation and was subject to previous exploration in the late 1980s. Mkango completed an updated Pre-Feasibility Study for the project in November 2015 and a Feasibility Study is currently underway, the initial phases of which included a 10,900 metre drilling programme and an updated mineral resource estimate, announced in February 2019. In March 2019, the Company announced receipt of a £7 million (C$12.3 million) investment from Talaxis to fund completion of the Feasibility Study. Following completion of the Feasibility Study, Talaxis has an option to acquire a further 26% interest in Songwe by arranging financing for project development including funding the equity component thereof.

The main exploration targets in Mkango’s remaining three 100% held licences are, in the Thambani licence, uranium, niobium, tantalum and zircon, in the Chimimbe Hill licence, nickel and cobalt, and in the Mchinji licence, rutile, nickel, cobalt, base metals and graphite. Mkango recently completed an extensive exploration program following a new rutile discovery within the Mchinji licence.

Mkango also holds a 75.5% interest in Maginito (www.maginito.com) with the balance owned by Talaxis. Maginito was established by Mkango and Talaxis to pursue downstream green technology opportunities in the rare earths supply chain, encompassing neodymium (NdFeB) magnet recycling as well as innovative rare earth alloy, magnet and separation technologies.

Maginito’s strategy is underpinned by offtake rights for sustainably sourced primary and secondary raw materials, and geared to accelerating growth in the electric vehicle sector, wind power generation and other industries driven by decarbonization of the economy.

For more information, please visit www.mkango.ca.

About Talaxis

Founded in 2016, Talaxis is a wholly-owned subsidiary of Noble Group Holdings Limited and invests in and develops projects that are related to technology metals, with a special focus on rare earth elements. Talaxis focuses on battery and electric vehicle materials such as nickel, lithium, graphite and vanadium. Talaxis has supply chain partners in the upstream and midstream segments, and also focuses on research and development solutions for industrial consumers in the downstream segment. Talaxis prioritises sustainable ventures with a strong emphasis on corporate social responsibility. These include projects that contribute to the decarbonisation of the economy and that are aligned with the United Nations Sustainable Development Goals.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement may have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango, its business and the Project. Generally, forward looking statements can be identified by the use of words such as “plans”, “expects” or “is expected”, “scheduled”, “estimates” “intends”, “anticipates”, “believes”, or variations of such words and phrases, or statements that certain actions, events or results “can”, “may”, “could”, “would”, “should”, “might” or “will”, occur or be achieved, or the negative connotations thereof. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, governmental action relating to COVID-19, COVID-19 and other market effects on global demand for the metals and associated downstream products for which Mkango is exploring, researching and developing, the positive results of a feasibility study on the Project and delays in obtaining financing or governmental or stock exchange approvals. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

For further information on Mkango, please contact:

Mkango Resources Limited

William Dawes                        
Chief Executive Officer                
[email protected]                 
Canada: +1 403 444 5979

Alexander Lemon
President
[email protected]

www.mkango.ca
@MkangoResources

Blytheweigh

Financial Public Relations
Tim Blythe
UK: +44 207 138 3204

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker
Jeff Keating, Caroline Rowe
UK: +44 20 3470 0470

Alternative Resource Capital

Joint Broker
Alex Wood
UK: +44 20 7186 9004

Bacchus Capital Advisers

Strategic and Financial Adviser
Richard Allan
UK: +44 20 3848 1642


The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.



Posted on

Skanska builds Hartsfield-Jackson Atlanta International Airport Concourse T-North Extension in Georgia, USA, for about USD 56M, about SEK 460M

PR Newswire

ÖSTERSUND, Sweden, Jan. 7, 2021 /PRNewswire/ — Skanska has signed an additional contract with Hartsfield-Jackson Atlanta International Airport to construct the Concourse T-North Extension and modernization project in Atlanta, Georgia, USA, in a Skanska-led joint venture along with New South Construction, FS360 and Synergy Construction. Skanska’s share of the contract is worth about USD 56M, about SEK 460M, which will be included in the US order bookings for the fourth quarter 2020.

The expansion and modernization at the world’s busiest passenger airport will include the construction of five additional gates at the north end of Concourse T at the Airport, in addition to rebuilding a major portion of the North Terminal exit road, construct a Delta Air Lines ground support equipment facility and a fire station, as well as oversee relocations to the utilities’ infrastructure. The project will enhance the level of customer service by increasing capacity and updating the aesthetic appeal.

Construction begins January 2021, and completion is scheduled for December 2022.

Skanska is one of the leading construction and development companies in USA, specializing in building construction, civil infrastructure and developing commercial properties in select U.S. markets. Skanska USA had sales of SEK 74 billion and about 7,900 employees in its operations in 2019.

CONTACT:

For further information please contact:

Maritza E. Ferreira, Communications Director, Skanska USA, tel +1 (404) 946 75 21
Jacob Birkeland, Head of Media Relations & Public Affairs, Skanska AB, tel +46 (0)10 449 31 34
Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at

www.skanska.com
.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skanska/r/skanska-builds-hartsfield-jackson-atlanta-international-airport-concourse-t-north-extension-in-georg,c3264705

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/skanska-builds-hartsfield-jackson-atlanta-international-airport-concourse-t-north-extension-in-georgia-usa-for-about-usd-56m-about-sek-460m-301202562.html

SOURCE Skanska

Posted on

Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation

Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation

  • Coverage initiated with “Buy” rating and €2.30 price target for Jefferies and €2.60 price target for Kempen

MONTPELLIER, France–(BUSINESS WIRE)–
Regulatory News:

Sensorion (Paris:ALSEN)(FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the investment banks Jefferies and Kempen have initiated analyst coverage of Sensorion.

Jefferies initiated coverage with a “Buy” rating and a price target of €2.30 and Kempen initiated coverage with a “Buy” rating and a price target of €2.60.

Jefferies and Kempen join Chardan and Bryan Garnier & Co, whose analysts also initiated coverage on the company with a “Buy” rating in 2020 and 2019 respectively.

All reports on Sensorion prepared by analysts represent the views of those analysts and not necessarily those of Sensorion. Sensorion is not responsible for the content, accuracy, or timing of analyst reports. A copy of the full analysts’ notes can be obtained directly from the banks. By referring to these analysts or distributing their opinions, Sensorion does not in any way commit itself to the validity of such information, conclusions or recommendations.

It is reminded that Jefferies acted as Sole Global Coordinator and Joint Bookrunner, and Kempen acted as Joint Bookrunner in the €31m private placement completed on September 2020.

This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. In the second half of 2019, Sensorion initiated two preclinical gene therapy programs aimed at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is potentially uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.

http://www.sensorion-pharma.com

Label: SENSORION

ISIN: FR0012596468

Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2020 Half-Year financial report published on October 21, 2020 and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Press Relations

Sophie Baumont

LifeSci Advisors

[email protected]

+33 6 27 74 74 49

Investor Relations

Ligia Vela-Reid

LifeSci Advisors

[email protected]

+44 74 13 82 53 10

KEYWORDS: France Europe

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Medical Devices

MEDIA:

Posted on

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

Montrouge, France, January 7, 2021

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it has determined that it now qualifies as a U.S. domestic issuer rather than a foreign private issuer in the United States.

As of January 1, 2021, DBV Technologies is subject to U.S. Securities and Exchange Commission (SEC) and other rules and regulations applicable to U.S. domestic issuers, in addition to applicable French and EU regulations. DBV will be required to file with the SEC periodic reports (including current reports on Form 8-K and quarterly reports on Form 10-Q) and registration statements on U.S. domestic issuer forms. Pursuant to SEC rules, the Company will prepare its consolidated financial statements in accordance with generally accepted accounting principles in the United States (US GAAP). Additionally, the Company will continue to prepare consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union, for release in France and the European Union. Beginning January 1, 2021, the Company’s consolidated financial information filed with the SEC and with the Autorité des marchés financiers (AMF) (including in the Company’s Universal Registration Document) will be reported in US dollars.

Today, the Company also announced that the process implementing the Employment Safeguard Plan in France has been approved. DBV initiated this global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. The full implementation of the restructuring plan will result in a reduction of more than 200 jobs, resulting in a remaining global team of 90 individuals dedicated to the pursuit of innovation and scientific development of novel therapies. DBV expects all head-count reductions to be completed by the end of the first quarter of 2021. DBV will retain its core expertise in clinical development, patch engineering and manufacturing, U.S. and EU market insights, and EPIT biology.

“This approval represents a significant milestone for DBV,” said Daniel Tasse, Chief Executive Officer. “We believe our restructuring efforts will yield a leaner organization, enable us to achieve greater financial flexibility, and allow us to best position ourselves as we navigate the late stages of clinical development. I would like to thank all of our DBV colleagues, past and present, who have contributed to the advancement of epicutaneous immunotherapy and to celebrate the talented team that will propel us forward. This is a team of individuals who embody our corporate values of collaboration, curiosity, courage, and credibility.”

As a result of the ongoing global restructuring, DBV has been able to simplify business processes across the Company’s global operations. DBV Technologies expects continued deceleration in its average monthly cash burn through the second half of 2021. DBV Technologies expects full implementation of the organization-wide cost reduction measures to be completed by the second half of 2021, at which point DBV forecasts it will have reduced its average monthly cash burn by 40-50% as compared to the first half of 2020. Based on current assumptions regarding the progress of its regulatory dossier and in light of the final approval of the plan, DBV expects these cost-reduction efforts to significantly extend the Company’s cash runway to the second half of 2022.  

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the implementation of the Company’s global restructuring plan, the potential benefits of the proposed restructuring of the Company’s business and the Company’s ability to realize those benefits,  potential cost savings, the Company’s forecast of its cash runway and reduced monthly cash burn, the preparation of new and additional financial statements, and anticipated future filings with U.S., E.U., and French securities regulators. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, the Company’s ability to successfully execute on its restructuring plans, the Company’s ability to prepare financial statements in accordance with US GAAP, and risks related to the regulatory and compliance burden associated with reporting as a U.S. domestic issuer. Furthermore, the timing of any action by any regulatory entity cannot be guaranteed, particularly in light of the COVID-19 pandemic. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in the Company’s regulatory filings with the French AMF, the Company’s SEC filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this press release.

Investor Relations Contact

Anne Pollak
+ 1 (857) 529-2363
[email protected]

Media Contact

Angela Marcucci
+1 (646) 842-2393
[email protected]

Attachment



Posted on

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

Basel, Switzerland, January 07, 2021

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that patient enrolment has been completed in the phase 3 study with the antifungal isavuconazole (Cresemba®), which is conducted in Japan by Basilea’s partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma). The study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.1

David Veitch, Chief Executive Officer of Basilea, said: “The completion of patient enrolment in the phase 3 study is an important step in the development of Cresemba in Japan, where we see one of the commercially most important opportunities for the drug. Our partner Asahi Kasei Pharma expects to obtain study results in the second half of 2021, which will be the next major milestone for potentially making Cresemba available for patients in Japan.“

The partnership between Basilea and Asahi Kasei Pharma was established in September 2016. Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan. Basilea received an upfront payment of CHF 7 million and will be eligible to receive up to approximately CHF 60 million of additional payments upon achievement of regulatory and commercial milestones. Basilea will also receive double-digit tiered royalties on product sales in Japan.

Cresemba has been approved in more than 50 countries to date and is currently marketed in 48 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of September 2020, total “in-market” sales of Cresemba amounted to USD 244 million, a more than 28 percent growth year-on-year.2

About isavuconazole (Cresemba)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.3 Cresemba is also approved in the United States and several additional countries in Europe and beyond.4 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

About invasive aspergillosis and mucormycosis

Invasive aspergillosis and mucormycosis are life-threatening fungal infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer). Both infections are associated with high morbidity and mortality.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Phone +41 61 606 1102
E-mail [email protected]

[email protected]

This press release can be downloaded from www.basilea.com

References

  1. Clinicaltrials.gov identifier NCT03471988
  2. IQVIA, September 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  3. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: January 06, 2021]
  4. The registration status and approved indications may vary from country to country.

 Attachment:



Posted on

Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.

Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.

  • Latest addition to Alcon’s intraocular lens (IOL) portfolio expands surgeons’ presbyopia-correcting IOL (PC-IOL) offerings
  • Vivity X-WAVE technology delivers extended range of vision while maintaining a monofocal-like visual disturbance profile*1,2
  • PC-IOL option for cataract patients who may not be a candidate for a diffractive IOL

GENEVA–(BUSINESS WIRE)–
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth of focus intraocular lens (IOL) in the U.S. – the AcrySof® IQ VivityTM IOL (Vivity). This new presbyopia-mitigating lens is now available to all U.S. ophthalmologists for patients undergoing cataract surgery. Cataracts are the most common cause of vision loss globally.3 The U.S. market is expected to grow to 5.4 million cataract surgeries by 2025.4 With the aging population, the number of people in the U.S. with cataracts is expected to double by 2050.3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005946/en/

Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractive X-WAVE™ technology, which stretches and shifts light without splitting it.1 Vivity delivers monofocal-quality distance (far) with excellent intermediate (at arm’s length) and functional near vision (up close).*2 The lens expands Alcon’s growing portfolio of presbyopia-mitigating IOLs to meet the needs of cataract patients who are interested in restoring their visual performance and improving their lifestyle.

“With the introduction of Vivity, Alcon continues to demonstrate our ongoing commitment to growing our IOL portfolio and delivering differentiated innovations that meet surgeon and patient needs,” said Sergio Duplan, President, North America at Alcon. “We now offer two next-generation presbyopia-mitigating IOL options, with the PanOptix Trifocal for patients who want to be more spectacle independent at all distances and Vivity for patients who seek to improve their intermediate and near vision, with a monofocal-like visual disturbance profile.”

Also available in toric designs, Vivity is built on Alcon’s trusted and proven AcrySof IQ IOL platform that has been implanted in more than 125 million eyes globally.5 According to results from a U.S. clinical trial, patients who had the Vivity lens implanted experienced renewed vision and lifestyle benefits, including:2

  • 94% and 92% of Vivity patients reported very good or good vision at distance and arm’s length, respectively, without glasses in bright light, with vision of 20/20 at distance and greater than 20/25 at intermediate*†2
  • Comparable visual disturbance profile to a monofocal IOL*2

“The Vivity lens is a disruptive technology that fills a gap for eye surgeons as a presbyopia-mitigating IOL option for those patients who are not candidates for a diffractive IOL platform, but want some spectacle independence,” said Dr. Cathleen McCabe, Chief Medical Officer, Eye Health America and Medical Director, The Eye Associates. “This lens has a monofocal-like visual disturbance profile, a low incidence of severe or very bothersome glare and halos, and provides a continuous extended range of vision which can meet the needs of many cataract patients.”

Vivity received FDA approval in February 2020, and it was made available to select U.S. ophthalmologists in September 2020 during a pilot phase, ahead of the current national launch.

Vivity is already available in some European markets, Australia, New Zealand and Canada and has been introduced to select ophthalmologists in Latin America. For more information regarding Vivity in the U.S., visit vivityview.com.

About Cataracts

A cataract is a cloudy area in the natural lens of the eye that affects vision. As a cataract develops, the eye’s lens gradually becomes hard and cloudy allowing less light to pass through, which makes it more difficult to see. The vast majority of cataracts result from normal aging, but radiation exposure, taking steroids, diabetes and eye trauma can accelerate their development.3 Cataracts are the most common age-related eye condition and the leading cause of preventable blindness.6 Twenty million people in the U.S. age 40 and older have cataracts.3 Cataracts are treated by removing the eye’s cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.7

About Presbyopia

Presbyopia is a common, age-related vision condition in which people have difficulty focusing on things up close. It involves the gradual loss of the eye’s ability to focus on close objects, such as smart phones, computers, books and menus.8 Almost everyone will experience presbyopia to some degree as they age, with symptoms often first appearing as an individual enters their 40s and continues to worsen into their 60s.8 In the U.S., an estimated 112 million people experience vision issues due to presbyopia – a number that’s expected to continue increasing.9 The condition is not a disease, so it cannot be cured; however, there are safe and effective ways to correct presbyopia, including eye glasses, contact lenses or refractive surgery.

About the AcrySof® IQ Vivity™ IOL

The non-diffractive AcrySof® IQ VivityTM Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof® IQ VivityTM IOL) is a UV-absorbing and blue light filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances.

Potential side effects: As with any surgery, there is an implicit risk, whether or not the IOL is implanted. The complications of the IOL implantation surgery ranges from minor side effects (usually temporary) to serious complications. Patients with previous illnesses or disorders (such as chronic infections of the eye or eyelids, or diabetes) may present a higher risk of complications. Temporary surgical complications include, but are not limited to, reactions to medications such as irritation or mild allergic response, bleeding, redness, itching of the eye, sensitivity to light, swelling, corneal edema (swelling of the cornea), problems with the iris, cell growth in the IOL, and an increase temporary eye pressure. There is a small risk of needing further surgical treatment (such as IOL replacement implanted by a different one or surgery to improve vision) after the implantation of the initial IOL.

ABOUT ALCON

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

References

  1. Alcon Data on File, 2019.
  2. AcrySof® IQ Vivity™ Extended Vision IOL DFU. Alcon Laboratories, Inc.; 2020.
  3. Cataract Data and Statistics. National Eye Institute. Accessed December 21, 2020. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/cataract-data-and-statistics.
  4. 2020 IOL Market Report – Mid Year Update, Market Scope, 08/28/2020, pp5, Table 47: Forecast for the IOL Market in the United States.
  5. Alcon Data on File, 2020.
  6. Centers for Disease Control and Prevention, Vision Health Initiative. Accessed December 21, 2020. https://www.cdc.gov/visionhealth/basics/ced/index.html.
  7. Cleveland Clinic, Cataracts. Accessed December 21, 2020. https://my.clevelandclinic.org/health/diseases/8589-cataracts.
  8. Mayo Clinic, Presbyopia. Accessed December 21, 2020. https://www.mayoclinic.org/diseases-conditions/presbyopia/symptoms-causes/syc-20363328.
  9. American Optometric Association: Optometric Clinical Practice Guideline, Care of the Patient with Presbyopia. Accessed December 21, 2020. https://www.aoa.org/documents/optometrists/CPG-17.pdf.

*Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof® IQ Vivity™ IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up

†Response to the following question in IOLSAT questionnaire at 6 months post-op (AcrySof® IQ Vivity™ IOL n = 106, monofocal n = 111): “Given your vision today, would you recommend the lenses you had implanted to your family or friends?”

Disclaimer

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

Connect with us on

Facebook

LinkedIn

Investor Relations

Christina Cheng

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

[email protected]

Media Relations

Blake Overby

+ 1 817 551 4328 (Fort Worth)

+ 1 682 321 2897 (Fort Worth)

[email protected]

KEYWORDS: Texas Europe Switzerland United States North America

INDUSTRY KEYWORDS: Health Optical Surgery

MEDIA:

Logo
Logo
Photo
Photo
Logo
Logo
Photo
Photo
AcrySof® IQ Vivity™ IOL packaging
Photo
Photo
Simulated Image Before and After Cataract Surgery (Photo: Business Wire)
Posted on

ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021

 

Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in the JP Morgan Virtual Healthcare Conference taking place January 11-14, 2021.  ObsEva will present on Thursday, January 14, 2021 at 7:30 a.m. Eastern Time (ET).

The presentation webcast will be available in the “Investors” section of ObsEva’s website www.ObsEva.com.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

For further information, please contact:

CEO Office Contact:

Shauna Dillon


[email protected]


+41 22 552 1550

 

 

 

Attachment



Posted on

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has entered into a committed equity purchase agreement (“Purchase Agreement”) for up to $40 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.

Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40 million American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company. LPC’s maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually agree to increase the maximum amount of such purchase. The purchase price for the ADSs to be purchased by LPC under a regular purchase will be the equal to the lower of (i) the lowest sale price for ADSs on the applicable purchase date, and (ii) the average of the three lowest closing sale prices for ADSs during the ten business days prior to the purchase date. There are no upper limits to the price LPC may pay to purchase common stock from the Company. Celyad Oncology controls the timing and amount of any future sales of ADSs to LPC. As part of the Purchase Agreement, LPC has agreed not to cause or engage in any manner whatsoever any direct or indirect short selling or hedging of Celyad Oncology’s shares of common stock. The Purchase Agreement may be terminated by Celyad Oncology at any time, at its sole discretion, without any additional cost or penalty.

In consideration for entering into the Purchase Agreement, at the signing of the Purchase Agreement, LPC received a commitment fee of $1 million comprised of $600,000 in cash and $400,000 in the form of a discount on the initial purchase of $2 million of ADSs under the equity facility.

Celyad Oncology currently intends to use the net proceeds from sales of ADSs under the Purchase Agreement with LPC for general corporate purposes, including but not limited to the research and development of Company’s clinical and preclinical CAR T cell therapy candidates.

“We are thrilled to announce today’s agreement with Lincoln Park, as the committed equity facility is expected to strengthen our current balance sheet while also providing us with access to future capital on an as needed basis,” commented Filippo Petti, Chief Executive Officer of Celyad Oncology. “In addition, the Company now has greater flexibility to further advance our pipeline of clinical and preclinical next-generation CAR T candidates for the treatment of cancers through several potential value-creating milestones over the next several quarters.”

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction. Additional information regarding the Purchase Agreement with LPC is available in Celyad Oncology’s Form 6-K filed with the SEC on January 7, 2021. The ADSs covered by the Purchase Agreement are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-248464) that was declared effective by the SEC on September 4, 2020. A prospectus supplement relating to the offering was filed by Celyad Oncology with the SEC on January 7, 2021 and is available on the SEC’s website at www.sec.gov or by request from Celyad Oncology S.A., Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Belgium.

Financial Update

As of December 31, 2020, the Company ended the year with an unaudited treasury position of €17.2 million ($21.2 million). The Company confirms its previous guidance that its existing treasury position, without proceeds from the LPC purchase agreement, should be sufficient to fund operating expenses and capital expenditure requirements, based on the current scope of activities, into the third quarter of 2021.

In addition, the Company expects that the net proceeds from the $40 million purchase agreement with LPC should help to extend the Company’s cash runway beyond the third quarter of 2021.

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: future sales of ADSs pursuant to the Purchase Agreement with LPC, the closing of the initial purchase of ADSs, cash position and cash runway. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
[email protected]

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]

Source: Celyad Oncology SA



Posted on

Medical Properties Trust Announces Pricing of Public Offering of Common Stock

Medical Properties Trust Announces Pricing of Public Offering of Common Stock

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Medical Properties Trust, Inc. (the “Company”) (NYSE: MPW) announced today that it has priced an underwritten public offering of 32,000,000 shares of its common stock at a public offering price of $20.05 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of its common stock. The Company estimates that the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $618.1 million, or approximately $711.0 million if the underwriters’ option to purchase additional shares is exercised in full.

The Company intends to use the net proceeds from the offering to fund in part the previously announced transactions related to the acquisition of a portfolio of behavioral healthcare real estate assets located throughout the United Kingdom currently owned and operated by the Priory Group (“Priory”), a leading private provider of behavioral care in the United Kingdom, as well as the related costs and expenses of the transactions. The offering is not conditioned upon the successful completion of the Priory acquisition. The Company intends to use any remaining balance of the net proceeds from the offering (or if the Priory acquisition is not completed) for general corporate purposes, which may include repaying indebtedness (including amounts outstanding from time to time under its revolving credit facility and/or term loan facilities), working capital and capital expenditures, and potential future acquisitions.

Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan, Barclays, KeyBanc Capital Markets, Credit Agricole CIB, Credit Suisse, MUFG, RBC Capital Markets, Stifel, Truist Securities and Wells Fargo Securities acted as joint book running managers for the offering, and BNP Paribas, Mizuho Securities and Scotiabank acted as co-managers for the offering. The offering is expected to close on January 11, 2021, subject to customary closing conditions. All of the shares of common stock will be issued under the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, a copy of the preliminary prospectus supplement, final prospectus supplement and the prospectus relating to the offering may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, by phone at 866-471-2526 or by email at [email protected], BofA Securities, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at [email protected], and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204 or by email at [email protected], or by visiting the EDGAR database on the SEC’s web site at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any shares of the Company’s common stock, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed to acquire and develop net-leased hospital facilities. The Company’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

This press release includes “forward-looking statements” within the meaning of securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding the Company’s plans, strategies, objectives, targets, future expansion and development activities and expected financial performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward‐looking statements, including without limitation: the satisfaction of all conditions to, and the timely closing (if at all), of the Priory acquisition and related transactions; the risk that this offering may not be completed on the proposed terms, if at all; the ability of the Company’s tenants to meet the terms of their agreements; expected payout ratio; the amount of acquisitions of healthcare real estate, if any; capital markets conditions; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in certain hospital operations and the timing of such income; the payment of future dividends, if any; completion of additional debt or equity arrangements, and additional investments; national and international economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular; and the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis, and the factors referenced under the section captioned “Item 1.A Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2019 and our Form 10-Q for the quarter ended March 31, 2020. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and the Company disclaims any responsibility to update such information.

Drew Babin, CFA

Senior Managing Director – Corporate Communications

Medical Properties Trust, Inc.

(646) 884-9809

[email protected]

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Hospitals Construction & Property Health REIT

MEDIA:

Logo
Logo